XML 56 R45.htm IDEA: XBRL DOCUMENT
v3.23.1

Other Equity Investments - Additional Information (Detail) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended |
--- | --- | --- | ---
Oct. 31, 2021 | Oct. 31, 2019 | Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |
Unrealized gain (loss) on ongoing mark-to-market adjustments of investment in equity security |  |  | $ (6,194) | $ (11,622) |  |
Fair value of warrants |  |  | 700 |  | $ 600 |
Realized losses recognized on investment in equity securities |  |  | (7,158) | 1,244 |  |
Equity security investment |  |  | 49,803 |  | 43,653 | [1]
LianBio |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |
Equity security investment |  |  | 9,800 |  | $ 8,200 |
LianBio | Equity Method Investee's IPO |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |
Unrealized gain (loss) on ongoing mark-to-market adjustments of investment in equity security |  |  | 1,600 | $ (12,300) |  |
Bridge Bio Pharma Limited Liability Company | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd | LianBio |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |
Ownership interest |  | 10.00% |  |  |  |
Warrant to purchase percentage |  | 10.00% |  |  |  |
Warrants to purchase common stock | 347,569 |  |  |  |  |
Pelle Pharm Inc [Member] |  |  |  |  |  |
Schedule Of Equity Method Investments [Line Items] |  |  |  |  |  |
Realized losses recognized on investment in equity securities |  |  | $ 1,200 |  |  |
[1] | The condensed consolidated balance sheet as of December 31, 2022 is derived from the audited consolidated financial statements as of that date.

X
- Definition Warrant to purchase percentage. + References No definition available. + Details
Name: | bbio_WarrantToPurchasePercentage
Namespace Prefix: | bbio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warrant to purchase shares of common stock + References No definition available. + Details
Name: | bbio_WarrantToPurchaseSharesOfCommonStock
Namespace Prefix: | bbio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 45 -Paragraph 1A -URI https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740 + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 + Details
Name: | us-gaap_EquitySecuritiesFvNiRealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714 + Details
Name: | us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ScheduleOfEquityMethodInvestmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value portion of warrants not settleable in cash classified as equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258 + Details
Name: | us-gaap_WarrantsNotSettleableInCashFairValueDisclosure
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bbio_LianBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=bbio_EquityMethodInvesteesIpoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bbio_BridgeBioPharmaLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bbio_EntitiesAffiliatedWithPerceptiveLifeSciencesMasterFundLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=bbio_PellePharmIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |